[DOI] [PMC free article] [PubMed] [Google Scholar] 707
However, if reclassification does occur, it may create both opportunity and operational strain across clinical programs, pharmacy networks, compliance infrastructure, and financial models
Injections are particularly good in these cases, as they bypass the tract for higher absorption rates than with food or oral supplements
H.JosephN.GaoJ.et al
What they found: In normal obese mice: AOD-9604 reduced body fat by 21 % vs placebo, hGH by 24 % The AOD-9604 effect was fully dependent on the 3-adrenergic receptor , in knock-out mice no effect The hGH effect was partly independent of 3-AR , in knock-out mice there was still ~10 % fat reduction AOD-9604 did not raise IGF-1 (control level), whereas hGH raised IGF-1 by 80 % No changes in growth, organ weights (except adipose tissue), fasting insulin Why it matters: The study provided the mechanistic basis for AOD-9604 and confirmed the key business hypothesis: it is possible to separate the lipolytic effect of GH from its growth effect
